From: Inflammasome inhibitors: promising therapeutic approaches against cancer
Drug | Target | Effective cancer type | Clinical trials | Reference |
---|---|---|---|---|
Thalidomide | Caspase-1 | Prostate cancer | Phase II | [54] |
Multiple myeloma | Phase III | [55] | ||
Anakinra | IL-1R | Melanoma | N/A | [56] |
Breast cancer | [57] | |||
Multiple myeloma | Phase II | [58] | ||
P2X7R antagonist | P2X7R | Prostate cancer | N/A | [59] |
Pancreatic ductal adenocarcinoma (PDAC) | ||||
Osteosarcoma | [62] | |||
Multiple myeloma | [63] | |||
Head and neck squamous cell carcinoma | [64] | |||
Colorectal cancer | [65] | |||
Basal cell carcinoma | Phase I | [66] | ||
Parthenolide | NF-κB | Gastric cancer | N/A | [67] |
Colorectal cancer | [68] | |||
Pancreatic adenocarcinoma | [69] | |||
Nasopharyngeal carcinoma | [70] | |||
Andrographolide | NF-κB | Insulinoma | N/A | [71] |
Colorectal cancer | ||||
Breast cancer | ||||
Multiple myeloma | [77] | |||
Canakinumab | IL-1β | Lung cancer | Phase III (undergoing) | [78] |